QOL Medical, LLC
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 2017-01-01
- Employees
- -
- Market Cap
- -
- Website
- https://www.qol-net.co.jp/
Effects of Sacrosidase and Placebo in Subjects With Fructan Intolerance
Phase 2
Completed
- Conditions
- Fructan Intolerance
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-01-27
- Last Posted Date
- 2024-02-06
- Lead Sponsor
- QOL Medical, LLC
- Target Recruit Count
- 25
- Registration Number
- NCT05703009
- Locations
- 🇺🇸
Boston Specialists, Boston, Massachusetts, United States
7-Day Trial of Sucraid for Alleviating CSID Symptoms in Subjects With Low, Moderate, and Normal Sucrase Levels
Phase 4
Terminated
- Conditions
- Congenital Sucrase-Isomaltase DeficiencyCSIDSucrase Isomaltase Deficiency
- Interventions
- Biological: Sucraid (sacrosidase) Oral Solution 8500 IU/mL
- First Posted Date
- 2022-07-29
- Last Posted Date
- 2025-03-20
- Lead Sponsor
- QOL Medical, LLC
- Target Recruit Count
- 312
- Registration Number
- NCT05480761
- Locations
- 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸UCSF Benioff Children's Hospital Oakland, Oakland, California, United States
🇺🇸Kidz Medical, Coral Gables, Florida, United States
Adult Pilot Study for Reference Ranges and Optimal Cut-offs for the Sucrose Challenge Test and Sucrose Breath Test
Completed
- Conditions
- Congenital Sucrase-Isomaltase Deficiency
- Interventions
- Diagnostic Test: Sucrose Hydrogen Methane Breath Test
- First Posted Date
- 2021-09-16
- Last Posted Date
- 2022-05-24
- Lead Sponsor
- QOL Medical, LLC
- Target Recruit Count
- 211
- Registration Number
- NCT05045495
- Locations
- 🇺🇸
Science 37-Recruiting Nationally, Culver City, California, United States
A Trial to Evaluate the Frequency of Genetic Sucrase-Isomaltase Deficiency Genotypes, and the Efficacy and Safety of Sucraid® (Sacrosidase) Oral Solution in Subjects With Chronic Diarrhea and Sucrase Deficiency
Phase 4
Withdrawn
- Conditions
- Genetic Sucrase-Isomaltase Deficiency
- Interventions
- Drug: Placebo
- First Posted Date
- 2016-05-26
- Last Posted Date
- 2017-09-25
- Lead Sponsor
- QOL Medical, LLC
- Registration Number
- NCT02784067
Congenital Sucrase-Isomaltase Deficiency (CSID) Genetic Prevalence Study (GPS)
Completed
- Conditions
- Congenital Sucrase-isomaltase Deficiency (CSID)
- First Posted Date
- 2013-08-01
- Last Posted Date
- 2017-11-06
- Lead Sponsor
- QOL Medical, LLC
- Target Recruit Count
- 53
- Registration Number
- NCT01914003
- Locations
- 🇺🇸
Children's Hospital of Colorado, Aurora, Colorado, United States
🇺🇸Children's Center for Digestive Healthcare, Atlanta, Georgia, United States
🇺🇸Stony Brook University, Stony Brook, New York, United States
© Copyright 2025. All Rights Reserved by MedPath